肠道微生物对GLP-1受体激动剂治疗糖尿病效果的影响分析

Influence of Gut Microbes on the Efficacy of GLP-1 Receptor Agonists in the Treatment of Diabetes

目的 探讨肠道微生物对GLP-1受体激动剂治疗糖尿病效果的影响。方法 选取三明市第二医院2020年3月—2021年8月期间收治的110例糖尿病患者作为研究对象,按照随机数表法分为观察组(GLP-1受体激动剂+益生菌)和对照组(GLP-1受体激动剂)各55例,在治疗前后,进行肠道微生物、血糖、胰岛素、血脂的检测。结果 观察组患者治疗后的双歧杆菌、乳酸杆菌高于对照组,肠杆菌低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的空腹血糖水平、餐后2 h血糖水平低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的空腹胰岛素水平、餐后2 h胰岛素水平低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的总胆固醇水平、三酰甘油水平、低密度脂蛋白胆固醇水平低于对照组,差异有统计学意义(P<0.05)。结论 应用GLP-1受体激动剂治疗糖尿病,可纠正肠道菌群紊乱,有效提高血糖控制效果,改善患者的预后。

Objective To investigate the effect of gut microbes on the effect of GLP-1 receptor agonists on the treatment of diabetes.Methods A total of 110 diabetic patients admitted to the Second Hospital of Sanming City from March 2020 to August 2021 were selected as the research subjects.According to the random number table,they were divided into observation group(GLP-1 receptor agonist+probiotics)and control group(GLP-1 receptor agonist)with 55 cases in each group.Before and after treatment,gut microbes,blood glucose,insulin,and blood lipids were detected.Results After treatment,the Bifidobacterium and Lactobacillus in the observation group were higher than those in the control group,and the Enterobacteriaceae were lower than those in the control group,and the difference was statistically significant(P<0.05).The fasting blood glucose level and 2 h postprandial blood glucose level of the observation group after treatment were lower than those of the control group,and the difference was statistically significant(P<0.05).The levels of fasting insulin and 2 h postprandial insulin in the observation group after treatment were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of total cholesterol,triacylglycerol and low-density lipoprotein cholesterol in the observation group after treatment were lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of GLP-1 receptor agonist in the treatment of diabetes can correct the intestinal microbiota disorder,effectively improve the effect of blood glucose control and improve the prognosis of patients.